Jul 18, 2018 - It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
Jul 16, 2018 - Array's melanoma combo gets a guideline nod. Atossa looks for a window of opportunity in breast cancer. Astellas and Pfizer score widened approval for Xtandi.
Jul 13, 2018 - Financial & Investment Management Group Ltd Buys Omnicom Group Inc, Blackrock Credit Allocation Income Trust, Regeneron Pharmaceuticals Inc, Sells Schwab Intermediate-Term U.S. Treasury, Associated Capital Group Inc, Nokia Oyj, Stocks: OMC,BTZ,REGN,HBI,ARRY,IGR,AGIO,FWONK,BRK.A,GDO,FAX, release date:Jul 13, 2018
Jul 12, 2018 -
Wells Fargo initiated coverage of ARRIS International plc (NASDAQ: ARRS) with above-consensus estimates for 2018, 2019 and 2020.
Jun 01, 2018 - Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.
May 31, 2018 - FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.A clinical hold for CRISPR Therapeutics caused some concern but I p
May 22, 2018 - Recent weakness in the biotech sector is an opportunity to add to conviction holdings.My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received
May 21, 2018 - Achaogen breaks key support.Aimmune Therapeutics is a buy.Immune Design keeps its head above water.
May 19, 2018 - Immune Design and Viking Therapeutics are added to the win column.Exelixis makes up for its lost ground and is grounded on concrete support.As predicted, shares in Global Blood Therapeutics bled late
May 16, 2018 - Immune Design is beginning to run.Institutions place their bets on Viking Therapeutics. We will also do so, again.Array BioPharma becomes our second win.ChemoCentryx seems undervalued.